H.C. Wainwright Thinks Bioxcel Therapeutics’ Stock is Going to Recover
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics (BTAI), with a price target of $176.00. The company’s shares closed last Friday at $33.03, close to its 52-week low of $28.00.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 6.5% and a 47.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, EyePoint Pharmaceuticals, and Bausch Health Companies.
Bioxcel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $101.17, a 199.7% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $92.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.50 and a one-year low of $28.00. Currently, Bioxcel Therapeutics has an average volume of 421K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.